Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02249676 : Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders
PhasePhase 2
AgesMin: 18 Years Max: 80 Years
Inclusion Criteria:

- Clinically definite neuromyelitis optica or neuromyelitis optica spectrum disorder

- Age > 18 year

- EDSS > 3

- Progression continued relapses or worsening MRI after at least a year of attempted
therapy as evidenced by one or more of the following:

- Increase of 1 EDSS point (if baseline EDSS<5.0) or 0.5 EDSS points (if baseline
EDSS >5.5)

- Moderate-severe relapses in past 18 months

- Gadolinium enhancing lesions (double or triple dose Gd)

- 1 new T2 lesion

- Evidence of recent inflammatory disease, as evidenced by any one of the following:

- 1 moderate-severe relapses in past 18 months

- 1 Gd-enhancing lesions (single, double or triple dose Gd)

- 1 new T2 lesion

Exclusion Criteria:

- Received Immune inhibitors immunomodulator during the three months before the trial

- Significant cardiac, renal, or hepatic failure or any other disease that may affect
the results of the study

- Allergies

- Pregnant or possibly pregnant

- Cognitive decline to understand or sign the informed consent

- Brain tumor, HIV (+) tumor marker (+), blood pressure (BP): 200 /110 mmHg

- Judged not suitable by doctors
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557